Moderna Stock Falls After Lowering 2025 Forecast

Moderna's stock has plummeted by over 17% following the company's announcement of a $1 billion reduction in its 2025 sales forecast, now anticipated to be between $1.5 billion and $2.5 billion, down from the previous $2.5 billion to $3.5 billion. The drop in sales is attributed to weakened demand for its COVID-19 vaccine and a slow uptake of its new RSV vaccine. Moderna plans to cut costs by $1 billion in 2025 and an additional $500 million in 2026, as it also aims to focus on ten prioritized products and new product approvals over the next three years. The company's financial challenges are further compounded by increased competition in the COVID-19 market and falling vaccination rates. Despite these setbacks, Moderna is betting on its pipeline, including a combination vaccine for COVID-19 and influenza, to drive future growth.